Abstract
Erythropoietin (EPO) is an important hormone responsible for the stimulation of hematopoiesis which is impaired in a variety of diseases, such as chronic kidney disease, cancer chemotherapy, and the use of some anti-HIV drugs. Difficulties in the purification of endogenous EPO due to problems such as technical limitations, heterogeneity of target cells, inadequate amount and immunogenicity of the resultant product, had limited the entry of endogenous EPO in the clinical applications. The integration of medical biotechnology and hematology has introduced novel procedures for the production of human recombinant erythropoietin (rHuEPO), and other erythropoiesis-stimulating agents (ESAs). To investigate and produce rHuEPO, the first step is to recognize the molecular biology and functional pathways, structure, metabolism, and basic physiology of EPO. In this review, all clinical indications, side effects, challenges and notable points regarding EPO, rHuEPO, and other ESAs have also been addressed along with its molecular characterization, such as the modifications needed to optimize their rHuEPO biosynthesis.
Similar content being viewed by others
References
Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L et al (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21(4):414–421
Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E (1986) Structural characterization of human erythropoietin. J Biol Chem 261(7):3116–3121
Tran AD, Park S, Lisi PJ, Huynh OT, Ryall RR, Lane PA (1991) Separation of carbohydrate-mediated microheterogeneity of recombinant human erythropoietin by free solution capillary electrophoresis. Effects of pH, buffer type and organic additives. J Chromatogr 542(2):459–471
European Medicines Agency. Silapo: EPAR summary for the public 2007. http://www.emea.europa.eu/humandocs/PDFs/EPAR/silapo/H-760-en1.pdf. 4 Mar 2008
Morris AL, MacArthur MW, Hutchinson EG, Thornton JM (1992) Stereochemical quality of protein structure coordinates. Proteins 12(4):345–364
Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M (2008) Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111(10):5223–5232
La Ferla K, Reimann C, Jelkmann W, Hellwig-Burgel T (2002) Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J 16(13):1811–1813
Tarng DC, Huang TP, Chen TW, Yang WC (1999) Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int Suppl 69:S107–S118
Ng T, Marx G, Littlewood T, Macdougall I (2003) Recombinant erythropoietin in clinical practice. Postgrad Med J 79(933):367–376
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275
Maynard MA, Evans AJ, Shi W, Kim WY, Liu FF, Ohh M (2007) Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 6(22):2810–2816
Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23(24):9361–9374
Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC (2007) Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A 104(7):2301–2306
Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS et al (2007) Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Investig 117(4):1068–1077
Knabe W, Knerlich F, Washausen S, Kietzmann T, Siren AL, Brunnett G et al (2004) Expression patterns of erythropoietin and its receptor in the developing midbrain. Anat Embryol (Berl) 207(6):503–512
Knabe W, Siren AL, Ehrenreich H, Kuhn HJ (2005) Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia. Anat Embryol (Berl) 210(3):209–219
Shingo T, Sorokan ST, Shimazaki T, Weiss S (2001) Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21(24):9733–9743
Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M et al (2004) Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 9(1):42–54
Ehrenreich H, Hasselblatt M, Knerlich F, von Ahsen N, Jacob S, Sperling S et al (2005) A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci U S A 102(3):862–867
Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V et al (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8(4):666–676
Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B et al (2002) Erythropoietin receptor signalling is required for normal brain development. Development 129(2):505–516
Chong ZZ, Shang YC, Mu Y, Cui S, Yao Q, Maiese K (2013) Targeting erythropoietin for chronic neurodegenerative diseases. Expert Opin Ther Targets 17(6):707–720
Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P et al (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93(8):2627–2636
Buemi M, Lacquaniti A, Bolignano D, Maricchiolo G, Favaloro A, Buemi A et al (2009) The erythropoietin and regenerative medicine: a lesson from fish. Eur J Clin Investig 39(11):993–999
Elliott S, Sinclair AM (2012) The effect of erythropoietin on normal and neoplastic cells. Biologics 6:163–189
Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609(1–2):29–35
Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L et al (2010) Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115(21):4264–4272
Elliott S, Busse L, Swift S, McCaffery I, Rossi J, Kassner P et al (2012) Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant 27(7):2733–2745
Bartels C, Spate K, Krampe H, Ehrenreich H (2008) Recombinant human erythropoietin: novel strategies for neuroprotective/neuro-regenerative treatment of multiple sclerosis. Ther Adv Neurol Disord 1(3):193–206
Miyake T, Kung CK, Goldwasser E (1977) Purification of human erythropoietin. J Biol Chem 252(15):5558–5564
Sahmani M, Vatanmakanian M, Goudarzi M, Mobarra N, Azad M (2016) Microchips and their significance in isolation of circulating tumor cells and monitoring of cancers. Asian Pac J Cancer Prev 17(3):879–894
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2(8517):1175–1178
Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC et al (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111(12):992–1000
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316(2):73–78
Elliott S, Tomita D, Endre Z (2017) Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol 18(1):14
Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU et al (2018) Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with Aranesp therapy (TREAT). Am J Kidney Dis 73:309–315
Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R, ERA-EDTA ERBP Advisory Board (2009) Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 24(2):348–354
Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31(4):290–299
Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L (2004) Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 9(1):90–96
Jelkmann W (2013) Physiology and pharmacology of erythropoietin. Transfus Med Hemother 40(5):302–309
Roger SD (2006) Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) 11(4):341–346
Khalili H, Dashti S, Seifi S, Hadjibabaie M, Shafiei S (2006) Erythropoietin utilization evaluation and two brand products comparison, eprex and eposim. Tehran Univ Med J 64(2):1–2
Omrani H, Bashiri H, Reissi Dastgerdi D, Najafi F, Shafiezadeh S, Izadi N (2014) Comparison of the effect of various products of erythropoietin on hemoglobin level in hemodialysis patients. J Babol Univ Med Sci 16(2):23–28
Harzallah A, Zouaghi K, Dridi A, Boubaker K, Beji S, Ayari M et al (2015) Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients. Saudi J Kidney Dis Transplant 26(1):78–82
Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P et al (2006) Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 1(6):1211–1215
Piotr B, Mariusz S, Jacek R (2017) Methoxy polyethylene glycol-epoetin beta as a novel erythropoiesis stimulating agent with possible nephroprotective and cardiovascular protective effects in non-dialysis chronic kidney disease patients. Curr Pharm Biotechnol 18(4):303–308
Macdougall IC, Eckardt K-U (2006) Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 368(9539):947–953
Macdougall IC (2001) An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16(Suppl 3):14–21
Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C et al (2001) Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60(2):741–747
Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31(4):290–299
Egrie J (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity compared to recombinant human erythropoietin (rHuEPO). Blood 90:56a
Smith RE Jr, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H et al (2001) Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 84(Suppl 1):24–30
Egrie JC, Browne JK (2002) Development and characterization of darbepoetin alfa. Oncology (Williston Park) 16(10 Suppl 11):13–22
Desai J, Demetri GD (2005) Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Pract Res Clin Haematol 18(3):389–406
Joy MS (2002) Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother 36(7–8):1183–1192
Seastone DJ, Gerds AT (2015) Darbepoetin alfa for anemia with myelodysplastic syndrome. Expert Rev Hematol 8(2):139–146
Hermanson T, Bennett CL, Macdougall IC (2016) Peginesatide for the treatment of anemia due to chronic kidney disease—an unfulfilled promise. Expert Opin Drug Saf 15(10):1421–1426
US Food and Drug Administration (2013) Affymax and takeda announce a nationwide voluntary recall of all lots of OMONTYS® (peginesatide) injection, 23 Feb
Kamioner D (2012) Erythropoietin biosimilars currently available in hematology-oncology. Target Oncol 7(1):25–28
Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27(12):1724–1734
Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF (2000) Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39(35):10634–10640
Schriebl K, Trummer E, Lattenmayer C, Weik R, Kunert R, Muller D et al (2006) Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expr Purif 49(2):265–275
Eskandari F, Allahverdi A, Nasiri H, Azad M, Kalantari N, Soleimani M et al (2015) Nanofiber expansion of umbilical cord blood hematopoietic stem cells. Iran J Pediatr Hematol Oncol 5(4):170–178
Matsushita S, Chuang VT, Kanazawa M, Tanase S, Kawai K, Maruyama T et al (2006) Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin. Pharm Res 23(5):882–891
Bai Y, Shen W-C (2006) Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm Res 23(9):2116–2121
Evers TH, van Dongen EM, Faesen AC, Meijer E, Merkx M (2006) Quantitative understanding of the energy transfer between fluorescent proteins connected via flexible peptide linkers. Biochemistry 45(44):13183–13192
Joung CH, Shin JY, Koo JK, Lim JJ, Wang JS, Lee SJ et al (2009) Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expr Purif 68(2):137–145
Vijayakumar S, Thilaka GK (2014) Synthetic human erythropertin gene-construction, cloning and sequencing. Int J Pharm Sci Rev Res 26:75–78
Fishbane S, Spinowitz B (2018) Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis 71(3):423–435
Ma JZ, Ebben J, Xia H, Collins AJ (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10(3):610–619
Greenbaum LA (2005) Anemia in children with chronic kidney disease. Adv Chronic Kidney Dis 12(4):385–396
Atkinson MA, Furth SL (2011) Anemia in children with chronic kidney disease. Nat Rev Nephrol 7(11):635
Koury MJ, Haase VH (2015) Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol 11(7):394–410
Macdougall IC (1998) Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 13(Suppl 2):23–27
Bolanos L, Castro P, Falcon TG, Mouzo R, Varela JM (2002) Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 22(1):67–72
Wang H, Fan J, Chen M, Yao Q, Gao Z, Zhang G et al (2017) rhEPO enhances cellular anti-oxidant capacity to protect long-term cultured aging primary nerve cells. J Mol Neurosci 62(3–4):291–303
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL et al (2010) American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996–5010
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM et al (2013) Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Cancer Netw 11(7):838–874
Burstein SA, Boyd CN, Dale GL (1985) Quantitation of megakaryocytopoiesis in liquid culture by enzymatic determination of acetylcholinesterase. J Cell Physiol 122(1):159–165
Levine RF, Hazzard KC, Lamberg JD (1982) The significance of megakaryocyte size. Blood 60(5):1122–1131
Ishibashi T, Koziol J, Burstein S (1987) Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Investig 79(1):286–289
Azad M, Goudarzi M, Sahmani M, Dehghanifard A, Mobarra N, Vatanmakanian M et al (2015) Correlation between methylation and expression level of P15 and P16 genes during differentiation of cord blood stem cells into erythroid lineage mediated by erythropoietin. Nov Biomed 1:6–12
Gershon SK, Luksenburg H, Cote TR, Braun MM (2002) Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 346(20):1584–1586
Casadevall N (2002) Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 17(suppl_5):42–47
Iki S, Yagisawa M, Ohbayashi Y, Sato H, Urabe A (1991) Adverse effect of erythropoietin in myeloproliferative disorders. Lancet 337(8734):187–188
Bauer E, Danhauser-Riedl S, De Riese W, Raab HR, Sandner S, Meyer HJ et al (1992) Effects of recombinant human erythropoietin on clonogenic growth of primary human tumour specimens in vitro. Eur J Cancer 28A(10):1769
Poniewierska-Baran A, Rajewska-Majchrzak J, Ratajczak MZ (2017) Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications. J Cancer Stem Cell Res 5:e1003
Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M (1993) Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43(5):1010–1014
Ng TMG, Littlewood T, Macdougall I (2003) Recombinant erythropoietin in clinical practice. Postgrad Med J 79(933):367–376
MPR (2018) EPOGEN Dosage & Rx Info. [Cited 15 march 2019]. http://www.empr.com/epogen/drug/1532
Medscape (2018) darbepoetin alfa (Rx). [Cited 24 march 2019]. https://reference.medscape.com/drug/aranesp-darbepoetin-alfa-342150
DrugBank (2015) Peginesatide. [Cited 17 April 2019]. https://www.drugbank.ca/drugs/DB08894
Medscape (2018) peginesatide (Discontinued). [Cited 7 march 2019]. https://reference.medscape.com/drug/omontys-peginesatide-999736
Drugs.com (2018) Mircera Dosage. [Cited 7 march 2019]. https://www.drugs.com/dosage/mircera.html
European Medicines Agency (EMA) (2018) NeoRecormon. [Cited 10 April 2019]. https://www.ema.europa.eu/medicines/human/EPAR/neorecormon
Medicine UK (2015) NeoRecormon (Package leaflet: Information for the user). [Cited 18 April 2019]. https://www.medicines.org.uk/emc/files/pil.1538.pdf
Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S et al (2018) Comparing therapeutic efficacy and safety of epoetin beta and epoetin alfa in the treatment of anemia in end-stage renal disease hemodialysis patients. Am J Nephrol 48(4):251–259
Wilhelm-Leen ER, Winkelmayer WC (2015) Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis 66(1):69–74
Hermanson T, Bennett CL, Macdougall IC (2016) Peginesatide for the treatment of anemia due to chronic kidney disease—an unfulfilled promise. Expert Opin Drug Saf 15(10):1421–1426
Tsuruya K, Uemura Y, Hirakata H, Kitazono T, Tsubakihara Y, Suzuki M et al (2017) Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials. Nephrology (Carlton) 22(10):769–775
Kawai T, Kusano Y, Yamada K, Ueda C, Kawai A, Masaki T (2018) Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan. J Artif Organs 22:146–153
Acknowledgements
The authors declare that there are no acknowledgements.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Moradi, Z., Maali, A., Shad, J.S. et al. Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach. Indian J Hematol Blood Transfus 36, 26–36 (2020). https://doi.org/10.1007/s12288-019-01170-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-019-01170-1